Under construction – not a live service
Sign in
Taking people in CzechiaNo phase

Light-Based Scanning to Help Diagnose Bile Duct Cancer

Tests a light-based scan during bile duct endoscopy in adults with suspected bile duct cancer.

Plain-language title generated from the registry record
Registry title: Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study

Key facts

Where
Olomouc, CzechiaSee the site

Where in Czechia

  • Peter SlodičkaOlomouc, CzechiaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
University Hospital Olomouc
Trial code
NCT06964425
Record updated
2 July 2025
Original description
Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.Read full original descriptionShow less

Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma

Diagnosis of extrahepatic cholangiocarcinoma is challenging because the yield of imaging and tissue sampling is limited. Raman spectroscopy is an optical method based on the analysis of scattered monochromatic light. Raman spectroscopy is able to provide a molecular 'fingerprint' of the tissue to determine its type. The aim of this pilot study was to develop a methodology for in vivo Raman spectroscopy in bile ducts to improve the current diagnostic capabilities of extrahepatic cholangiocarcinoma.

Inclusion: person older than 18 years, who has known extrahepatic cholangiocarcinoma and is indicated for ERCP.

Exclusion: disagreement with the study.

ClinicalTrials.gov NCT06964425